This section collects basic demographic and general health data to contextualize reproductive and hormonal findings.
Full name or identifier
Date of birth
Current age
Assigned sex at birth
Gender identity
Height unit preference
cm
ft/in
Height (cm)
Height (ft/in)
Weight unit preference
kg
lbs
Weight (kg)
Weight (lbs)
Primary reason for this assessment
Do you menstruate or have you ever menstruated?
Age at menarche (first menstruation)
Please describe why (e.g. age-related cessation, medical condition, surgery, gender-affirming care)
Typical cycle length (days between first days of bleeding)
<21
21–25
26–30
31–35
36–40
>40
Highly variable
Not sure
Average bleeding duration (days)
Do you experience pain/cramps requiring medication or rest?
Rate your average premenstrual mood change severity
None
Mild
Moderate
Severe
Debilitating
Select any menstrual irregularities you experience
Skipped cycles
Very heavy flow
Spotting between cycles
Severe clotting
Cycles <21 days
Cycles >40 days
Do you track ovulation (basal body temp, LH strips, cervical mucus)?
Describe method and typical signs
Current fertility intention
Avoiding pregnancy
Not trying but not avoiding
Actively trying to conceive
Preserving fertility (egg/sperm freezing)
Using assisted reproduction
Done with childbearing
Unsure
Have you been trying to conceive for ≥12 months (or ≥6 if ≥35 years)?
Describe any investigations or treatments so far
Have you ever been pregnant or caused a pregnancy?
Total number of pregnancies (include losses)
Number of live births
Any history of ectopic pregnancy, miscarriage, or pregnancy loss?
Contraceptive method currently used (if any)
None
Condoms
Combined oral pill
Progestin-only pill
Injectable/implant
IUD hormonal
IUD copper
Fertility awareness
Withdrawal
Sterilization
Other
Over the last 4 weeks, rate your level of sexual desire
Very low
Low
Moderate
High
Very high
How often did you feel aroused during sexual activity?
Never
Rarely
Sometimes
Often
Always
Do you experience pain during or after intercourse?
Average frequency of sexual activity
Not sexually active
Less than monthly
Monthly
2–3 times/month
Weekly
2–3 times/week
Daily
Are you satisfied with your current sexual function?
Do you experience excessive facial/body hair growth?
Do you have persistent acne beyond adolescence?
Do you have darkened skin patches (neck, armpits, groin)?
Do you experience unexplained weight changes >5 kg in 6 months?
Do you have thinning scalp hair or male-pattern baldness?
Do you have persistent breast tenderness or nipple discharge?
Do you feel excessively hot or cold compared to others?
Do you have excessive sweating unrelated to exercise/heat?
Rate your average daily energy (1 = exhausted, 10 = excellent)
Do you experience severe energy crashes?
Do you have brain fog or memory lapses?
Do you feel irritable or anxious without clear cause?
Do you have depressive moods that worsen cyclically?
Do you wake feeling unrefreshed despite adequate sleep?
Do you experience rapid heartbeat or palpitations?
Average hours of sleep per night
<5
5–6
6–7
7–8
8–9
>9
Do you have trouble falling asleep?
Do you wake frequently during the night?
Do you experience night sweats?
Does your sleep quality vary with your cycle?
Do you snore loudly or gasp during sleep?
Do you experience bloating that fluctuates with your cycle?
Do you have constipation or diarrhea premenstrually?
Do you have intense sugar or salt cravings?
Do you feel nauseated or vomit during periods?
Do you have reflux or stomach pain?
Do you have joint pain that varies cyclically?
Do you experience leg cramps or restless legs?
Do you have dry skin or eczema flare-ups?
Do you notice changes in skin oiliness with cycles?
Do you have brittle nails or ridged nails?
Family history of reproductive cancers (breast, ovarian, endometrial, prostate)?
List affected relatives and ages at diagnosis
Personal history of polycystic ovary syndrome (PCOS)?
Personal history of endometriosis?
Personal history of thyroid disorders?
Personal history of diabetes or insulin resistance?
Previous surgery on reproductive organs?
Chemotherapy or pelvic radiation exposure?
Autoimmune condition (lupus, rheumatoid, etc.)?
Use of anabolic steroids or testosterone?
Chronic use of opioids or high-dose corticosteroids?
Exercise frequency
None
1–2 times/week
3–4 times/week
>5 times/week
Daily
Typical exercise intensity
Light (yoga, walking)
Moderate (jogging, cycling)
High (HIIT, competitive sports)
Do you smoke tobacco or vape?
Alcoholic drinks per week
Caffeinated cups per day
None
1
2–3
4–5
>5
Do you use recreational drugs?
Are you exposed to endocrine disruptors (pesticides, BPA, phthalates)?
Average stress level (1–10)
1–2
3–4
5–6
7–8
9–10
Do you work night shifts or rotating shifts?
Do you frequently cross time zones?
List all prescription medications and doses
List over-the-counter supplements/herbals
Are you on hormonal contraception or HRT?
Specify product, dose, and duration
Have you taken antibiotics in the last 6 months?
Are you on metformin or GLP-1 agonists?
Rate how much your hormonal/reproductive issues affect:
Not at all | Slightly | Moderately | Significantly | Extremely | |
|---|---|---|---|---|---|
Work productivity | |||||
Social activities | |||||
Intimate relationships | |||||
Self-esteem | |||||
Physical comfort |
Overall life satisfaction (1 = very dissatisfied, 10 = very satisfied)
Describe your top three goals from this assessment
Any additional comments or concerns
Analysis for Reproductive & Hormonal Vitality Assessment Form
Important Note: This analysis provides strategic insights to help you get the most from your form's submission data for powerful follow-up actions and better outcomes. Please remove this content before publishing the form to the public.
The Reproductive & Hormonal Vitality Assessment Form is a meticulously engineered instrument that balances clinical rigor with respondent friendliness. Its modular sectioning—from general demographics to quality-of-life impact—creates a logical narrative flow that reduces cognitive load and encourages completion. Conditional logic (e.g., menstruation history branches, fertility intention follow-ups) minimizes irrelevant questions, shortening the form dynamically and improving data fidelity. The inclusion of both metric and imperial unit preferences, matrix ratings, and yes-no gating demonstrates a user-centred design ethos that anticipates diverse populations and clinical contexts.
Equally impressive is the breadth of endocrine-relevant domains captured: menstrual patterns, sexual function, metabolic stigmata, sleep, GI complaints, and environmental exposures. This holistic sweep allows clinicians to detect sub-clinical phenotypes (e.g., cyclic joint pain hinting at estrogen fluctuations) and cross-validate patient narratives with objective symptom clusters. From a research standpoint, the instrument yields granular phenotypic data suitable for clustering analyses, predictive modelling, and personalised intervention trials, all while remaining compliant with emerging data-minimisation standards by avoiding free-text identifiers beyond name and DOB.
This field serves as the linchpin for longitudinal tracking and integration with electronic health records. By permitting a pseudonymous identifier, the form respects privacy regulations while still enabling clinicians to link sequential assessments over time. The open-text format accommodates cultural naming conventions that fixed fields often marginalise, enhancing inclusivity.
From a data-quality perspective, the lack of validation rules could invite low-entropy entries such as "." or \"N/A\"; however, the mandatory flag ensures that at least some token is provided, which can be refined during follow-up consultations. The form could be strengthened with a gentle regex prompt encouraging at least two characters, but the current permissiveness reduces early-stage abandonment.
Privacy implications are mitigated by the meta-description’s assurance that data are used solely for vitality assessment, yet respondents should be informed if the identifier will be hashed upon submission. Transparency here bolsters trust and encourages candid disclosure in subsequent sections.
Capturing date of birth rather than just age permits precise life-stage stratification—crucial for interpreting FSH levels, AMH percentiles, and bone-density norms. The date field also auto-calculates current age elsewhere, eliminating entry errors that plague dual-field approaches.
Storing full dates can, however, increase re-identification risk when combined with other quasi-identifiers. The form mitigates this by not requesting exact birthplace or ZIP code, but additional safeguards such as date-shifting within a 7-day window for research datasets would future-proof against re-identification attacks.
UX friction is minimal because modern browsers surface native date-pickers on mobile, reducing keystrokes. Yet for populations in low-digitisation settings, a fallback mask (dd/mm/yyyy) should be documented; the current placeholder attribute is absent, so respondents may default to free-text formats that complicate parsing.
Redundant at first glance, this field acts as a real-time cross-check against the date-of-birth entry, flagging discrepancies that could signal data-entry errors or proxy reporting. Clinicians can instantly query a 25-year-old whose DOB implies 40 years, avoiding downstream clinical misinterpretation.
From a user-experience lens, seeing one’s age auto-populated can be reassuring, reinforcing system competency. However, if auto-calculation fails, the manual entry becomes an irritant; hence the form should dynamically populate and lock this field once DOB is entered, removing mandatory status to prevent validation conflicts.
Data-collection implications are trivial because age is a low-cardinality variable, yet it remains a powerful covariate for polycystic ovary syndrome and perimenopause modelling. Keeping it mandatory ensures completeness, but the form could store only age-bands (e.g., 18–25) in the research subset to further anonymise.
This question anchors normative hormone ranges and determines which menstrual or prostate-related modules surface downstream. By distinguishing assigned sex from gender identity, the form acknowledges transgender and intersex experiences without conflating biology with identity—an approach endorsed by both Endocrine Society and WPATH guidelines.
Offering \"Intersex\" and \"Prefer not to say\" options reduces alienation, but the form should clarify that selection will not trigger denial of care. A brief tooltip or hyperlink to a plain-language explanation would pre-empt mistrust, especially in jurisdictions with politicised healthcare climates.
Data quality benefits from a controlled vocabulary, enabling automated decision rules (e.g., trigger haemoglobin reference ranges). The mandatory flag is justified because sex-specific risk algorithms (e.g., FRAX for osteoporosis) require this field; omitting it would invalidate downstream clinical recommendations.
Capturing gender identity allows tailored counselling—trans men on testosterone may experience vaginal atrophy, whereas cis women may focus on oestrogen-sensitive migraines. The inclusive option list (Non-binary, Agender, Genderfluid, Other) surpasses legacy forms that force binary choices, thereby improving face validity and respondent dignity.
Mandatory status here is ethically sound yet operationally challenging: some respondents fear that disclosing non-cis identities could bias care. The form should explicitly state anti-discrimination policies and store responses in access-controlled fields. Pseudonymising this field for aggregate analytics can still yield vital epidemiological insights (e.g., rates of dysmenorrhoea in trans men not on testosterone).
From a UX standpoint, placing gender identity after assigned sex reduces priming effects, letting respondents answer authentically. An optional free-text \"Other\" field with 50-character limit would capture emergent identities without overwhelming downstream parsing pipelines.
Despite its strengths, the form is lengthy (≈90 questions), risking fatigue-induced drop-off at the 60% mark. Implementing a progress bar and allowing save-resume functionality would raise completion rates. Several yes-no questions could be collapsed into multi-select grids to shorten perceived length. Finally, the absence of consent checkboxes or data-retention disclosures may violate GDPR/CCPA; adding a layered consent section with granular opt-outs would future-proof compliance.
Mandatory Question Analysis for Reproductive & Hormonal Vitality Assessment Form
Important Note: This analysis provides strategic insights to help you get the most from your form's submission data for powerful follow-up actions and better outcomes. Please remove this content before publishing the form to the public.
Question: Full name or identifier
Justification: A mandatory identifier is indispensable for longitudinal tracking and safe clinical hand-offs. Without it, follow-up consultations, laboratory result linking, and referral letters become untraceable, jeopardising patient safety. The field’s pseudonymous flexibility respects privacy while still anchoring each dataset to a unique human being, ensuring that hormonal trends can be monitored across months or years.
Question: Date of birth
Justification: DOB is the cornerstone for age-adjusted normative ranges (e.g., FSH, AMH, TSH) and for determining fertility staging. Leaving it optional would force clinicians to guess chronological age, leading to misclassification of perimenopause or adolescent sub-fertility. Moreover, DOB enables automated risk calculators (osteoporosis, cardiovascular disease) that inform preventative strategies, making its capture non-negotiable for evidence-based care.
Question: Current age
Justification: While seemingly duplicative, mandatory age entry provides an immediate cross-validation against DOB, flagging keystroke errors that could propagate through dosage algorithms (e.g., clomiphene protocols). It also powers real-time decision rules within the form itself—such as triggering the ≥35-year sub-fertility prompt—ensuring that respondents receive age-appropriate questions without delay.
Question: Assigned sex at birth
Justification: Endocrine reference ranges, contraceptive contraindications, and cancer-risk algorithms are fundamentally sex-specific. Omitting this field would invalidate every downstream recommendation, from mammography thresholds to testosterone dosing. Mandatory capture ensures that clinical decision support tools fire correctly, protecting patients from dosing errors and missed screenings.
Question: Gender identity
Justification: Making gender identity mandatory is essential for equitable care: it flags potential hormone-drug interactions (e.g., testosterone in trans men) and guides culturally competent counselling. Without this data, clinicians may default to cis-normative protocols, overlooking unique needs such as cervical screening in trans men or fertility preservation in trans women. Mandatory status upholds ethical standards of patient-centred care.
The form adopts a conservative mandatory set—only five core demographic fields—striking an effective balance between data completeness and user burden. This minimal approach keeps initial friction low, allowing respondents to invest in the assessment before encountering deeper, optional modules. To maximise completion rates further, consider demoting \"Current age\" to auto-calculated read-only once DOB is entered, eliminating redundant entry while preserving data integrity.
For future iterations, explore conditional mandatoriness: if a respondent discloses menstrual irregularities, elevate cycle-length and bleeding-duration fields to mandatory within that branch. This dynamic strategy harvests critical data without imposing blanket requirements on non-menstruators. Finally, pair every mandatory field with concise help text explaining why it matters; transparency converts perceived bureaucracy into perceived value, reducing abandonment and fostering trust in the reproductive and hormonal vitality assessment process.
To configure an element, select it on the form.